Skip to main content

2 Result(s)

within Article Remove this filter Hardik Chandasana Remove this filter Internal Medicine Remove this filter

and

  1. Article

    Open Access

    Population Pharmacokinetic Modeling of Abacavir/Dolutegravir/Lamivudine to Support a Fixed-Dose Combination in Children with HIV-1

    Once-daily fixed-dose combinations (FDC) containing abacavir (ABC), dolutegravir (DTG), and lamivudine (3TC) have been approved in the US for adults and children with HIV weighing ≥ 6 kg. This analysis assesse...

    Hardik Chandasana, Sven C. van Dijkman, Rashmi Mehta… in Infectious Diseases and Therapy (2024)

    Download PDF (1620 KB) View Article

  2. Article

    Open Access

    Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents

    HIV treatment options remain limited in children. Dolutegravir is a potent and well-tolerated, once-daily HIV-1 integrase inhibitor recommended for HIV-1 infection in both adults and children down to 4 weeks o...

    Hardik Chandasana, Mita Thapar, Siobhan Hayes, Mark Baker… in Clinical Pharmacokinetics (2023)

    Download PDF (4189 KB) View Article